RxDoctor Payments Data

Angelo Tanna, MD

Ophthalmology · Chicago, ILNPI 1215960489

Payments from drug & device makers

$9,947in general payments, 2019–2025

Across 31 payments — averaging $320.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$6K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson Surgical Vision, Inc.$500
  • Alcon$417
  • Aerie Pharmaceuticals, Inc.$379
  • AbbVie$155
  • plus $280 from 4 others

What the payments were for

  • Consulting fees$6,57366%
  • Speaking & faculty fees$2,00020%
  • Food & beverage$1,35514%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,947 in reported general payments places this provider in the 85th percentile of 773 ophthalmology providers in Illinois.

See all ophthalmology providers in Illinois

Medicare billing

Part B allowed, 2024
$388,835
Medicare patients
844
Services billed
3,802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost253$128,205
RhopressaNetarsudil Mesylate195$106,526
Alphagan PBrimonidine Tartrate130$65,923
Brimonidine Tartrate800$51,941
RocklatanNetarsudil Mesylat/Latanoprost72$33,882
VyzultaLatanoprostene Bunod68$30,777
Latanoprost1,945$26,370
Brinzolamide121$25,172
SimbrinzaBrinzolamide/Brimonidine Tart74$22,385
Travoprost119$19,612
RestasisCyclosporine23$19,543
Timolol MaleateTimolol Maleate/Pf52$16,593
Travatan ZTravoprost29$16,330
AzoptBrinzolamide25$14,888
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol69$14,394

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Restasis, Combigan$155$221,125419 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$379$140,408267 claims
AlconSimbrinza, Azopt$417$37,27399 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 773 ophthalmology providers in Illinois.

Other ophthalmology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →